Private Payrolls Rise by 109000 in April Exceeding Expectations ADP Reports South Korea Deputy PM Urges AI Wealth to Benefit Public Amid Samsung Labor Unrest Adani Group Stocks in Focus PL Capital Highlights Growth Potential in Infrastructure and Energy US Fed Rate Hike in 2026 Market Debate Intensifies India Plans Major Overhaul of Tax Administration to Facilitate Smooth GST Rollout Markets React Optimistically as Iran Nuclear Talks Progress Amid Diplomatic Doubts BILL Q1 2026 Earnings EPS Surpasses Estimates by Nearly 20 on Operational Discipline AGNCP Q1 2026 Earnings Strong EPS Beat Signals Resilience in RateSensitive Preferred EVGN Q1 2026 Earnings EPS Misses Estimates as PreRevenue Biotech Continues RD Spend Village Farms International Inc VFF Q1 2026 Earnings EPS Slightly Misses Estimates Amid Cautious Outlook Universal Technical Institute Inc UTI Q1 2026 Earnings EPS Misses Estimates Amid Enrollment Headwinds Worthington Enterprises WOR Q1 2026 Earnings EPS Slightly Beats Estimates as Stock Gains 11 Xenetic Biosciences XBIO Modestly Advances as Biotech Stock Tests Key Resistance Zone Voyager Acquisition Corp VACH Surges 49 Potential Breakout From Consolidation Enact Holdings ACT Holds Steady at 4312 as Stock Tests Key Resistance Neumora Therapeutics NMRA Holds Steady at 185 as Stock Navigates Tight Range Yalla Group Limited YALA Holds Steady at 620 Amid Modest Gains Kevin Warsh Takes Over US Fed Amid AIDriven Economic Shift and Persistent Inflation US Payrolls Beat Expectations in April but Warning Signs Emerge Move Over Tesla Another RoboTaxi Stock Accelerates Its Autonomous Ambitions Money Market Account Rates Reach Up to 401 APY as of May 22 2026 Navigating Earnings Season Investors Business Dailys Guide to Analyst Estimates and Stocks to Watch Dow Nasdaq Futures Edge Higher as USIran Talks Boost Optimism SP 500 Eyes Eighth Weekly Gain Treasury Yields Edge Lower as Iran Peace Deal Optimism Tempers SafeHaven Demand CHCT Q1 2026 Earnings Massive EPS Surprise as Healthcare REIT Delivers Strong Operational Performance Cellectis CLLS Stock Dips 127 as Biotech Volatility Persists Key Support at 332 in Focus